Dynamic hyperinflammatory response assessment using HIC scores in COVID-19: application to a large series of patients receiving anakinra - Scorecard - MDSpire

Dynamic hyperinflammatory response assessment using HIC scores in COVID-19: application to a large series of patients receiving anakinra

  • By

  • Shirkhan Amikishiyev

  • Rabia Deniz

  • Mehmet Guven Gunver

  • Sarvan Aghamuradov

  • Nevzat Koca

  • Burak Ince

  • Murat Bektas

  • Aysenur Yilmaz

  • Yagmur Canturk

  • Gorkem Durak

  • Murat Kose

  • Mustafa Erelel

  • Arif Atahan Çağatay

  • Serap Simsek Yavuz

  • Sevgi Kalayoglu Besisik

  • Figen Esen

  • Ahmet Gül

  • May 22, 2026

  • 0 min

Share

Clinical Scorecard: Evaluation of Dynamic Hyperinflammatory Responses through HIC Scores in COVID-19: Insights from a Large Cohort Treated with Anakinra

At a Glance

CategoryDetail
ConditionCOVID-19 associated hyperinflammation (source needed)
Key MechanismsDysregulated innate immune responses and excessive production of proinflammatory cytokines (source needed)
Target PopulationHospitalized adult COVID-19 patients with hyperinflammation (HIC ≥35) (source needed)
Care SettingTertiary referral center (source needed)

Key Highlights

  • Overall mortality in the cohort was 12.8%.
  • Survivors achieved earlier CRP reduction compared to non-survivors.
  • Divergence in ΔHIC and inflammatory biomarkers emerged within 3–4 days.
  • Anakinra doses were adjusted based on clinical and laboratory parameters.

Guideline-Based Recommendations

Diagnosis

  • Use HIC score for early diagnosis of hyperinflammation in COVID-19 (source needed).

Management

  • Initiate anakinra when HIC is ≥35 but <70 (source needed).

Monitoring & Follow-up

  • Reassess treatment response after 3–4 days using ΔHIC and CRP kinetics (source needed).

Risks

  • Monitor for persistently elevated or rising HIC scores as a risk for non-survival (source needed).

Patient & Prescribing Data

218 hospitalized patients with hyperinflammation treated with anakinra.

Daily anakinra doses ranged from 100–800 mg/day, adjusted based on clinical and laboratory parameters.

Clinical Best Practices

  • Utilize HIC score for dynamic assessment of treatment response (source needed).
  • Monitor inflammatory biomarkers alongside HIC for better prognostic evaluation (source needed).

Related Resources & Content

Original Source(s)

Dynamic hyperinflammatory response assessment using HIC scores in COVID-19: application to a large series of patients receiving anakinra

  • by Shirkhan Amikishiyev, Rabia Deniz, Mehmet Guven Gunver, Sarvan Aghamuradov, Nevzat Koca, Burak Ince, Murat Bektas, Aysenur Yilmaz, Yagmur Canturk, Gorkem Durak, Murat Kose, Mustafa Erelel, Arif Atahan Çağatay, Serap Simsek Yavuz, Sevgi Kalayoglu Besisik, Figen Esen, Ahmet Gül

  • May 22, 2026

Related Content

Long-term epidemiological patterns of pediatric infectious diseases in an urban district of Shanghai, 2015–2023

Long COVID as a network disorder: a mechanism-anchored framework for biological stratification and therapeutic targeting

Case Report: Successful treatment of recurrent COVID-19 with intravenous immunoglobulin in a patient with rituximab-induced B-cell depletion and restoration of Fc-mediated effector functions